Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PJ020
- Development stage
- Unknown
- Lead developer
- Chongqing Peg-Bio Biopharm
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
PJ020 is a long-acting recombinant acylated glucagon-like peptide-2 (GLP-2) analogue being developed by Chongqing Peg-Bio Biopharm. It acts as a GLP-2 receptor agonist to promote intestinal epithelial growth and repair, thereby improving intestinal function. PJ020 is being developed for the prevention and treatment of chemotherapy-induced diarrhea (CID) or chemotherapy-induced intestinal damage, as well as short bowel syndrome (SBS) as a weekly formulation. It has received IND clearance in China and is in Phase 1 clinical development.
- Other names
- GLP-2 analogGLP2 analogGLP 2 analogWeekly GLP-2 formulationrecombinant acylated glucagon-like peptide-2 analogue重组酰化胰高血糖素样肽-2类似物
02
Targets
GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on PJ020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PJ020.